News/ News/ R&D Biogen’s ambitions in gene therapy hit by another failed pivotal trial Phil Taylor Biogen, gene therapy, Nightstar, ophthalmology, rare disease 0 Comment When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that Share X Biogen’s ambitions in gene therapy hit by another failed pivotal trial https://pharmaphorum.com/news/biogens-ambitions-in-gene-therapy-are-hit-by-a-second-failed-phase-3-trial/
News Biogen buys UK gene therapy firm Nightstar for $800m Richard Staines Biogen, M&A, Nightstar, ophthalmology, Roche 0 Comment Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies Share X Biogen buys UK gene therapy firm Nightstar for $800m https://pharmaphorum.com/news/biogen-buys-uk-gene-therapy-firm-nightstar-for-800m/
Biogen, gene therapy, Nightstar, ophthalmology, rare disease
0 Comment
